Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in IgA Vasculitis
NCT05329090Phase 3Completed
- Sponsor
- Hôpital Foch
- Start
- Mar 2022
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in immunoglobulin A vasculitis, sponsored by Hôpital Foch. Started Mar 2022; status: completed.
02
Drugs
rituximab
03
Conditions
immunoglobulin A vasculitis
Beyond the preview
Go deeper on NCT05329090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329090.